The St. Louis-based pharmacy benefit manager has been excluding treatments from its coverage since 2014 due to concerns over high drug costs. Express Scripts said the exclusions allow the company to better negotiate lower prices with drug companies and expects to save customers around $2.5 billion in 2018, compared to the $1.8 billion in savings this year.
Newly excluded drugs for 2018 include Amgen’s drug Neupogen — which boosts patients white blood cell counts during chemotherapy — and Eli Lilly’s osteoporosis drug Forteo. Express Scripts is also excluding coverage for EpiPen competitors like Kaleo’s Auvi-Q device and Impax Laboratories’ USP Auto-Injector.
To view Express Scripts’ full exclusion list, along with its preferred alternative drugs, click here.
More articles on supply chain:
Survey: 82% of drug, device execs say financial info most targeted asset in cyberattacks
FDA to pre-certify digital health companies in pilot program
4 thoughts on modernizing the supply chain with a Cardinal Health leader
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
